Biomarkers for Alzheimer's disease: current status and prospects for the future von Blennow, K., Zetterberg, H.

Volltext

CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology von Miners, J S, Kehoe, P G, Love, S, Zetterberg, H, Blennow, K

Volltext

Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology‐based cohort von Kovacs, G. G., Andreasson, U., Liman, V., Regelsberger, G., Lutz, M. I., Danics, K., Keller, E., Zetterberg, H., Blennow, K.

Volltext

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease von Salloway, S, Sperling, R, Gilman, S, Fox, N C, Blennow, K, Raskind, M, Sabbagh, M, Honig, L S, Doody, R, van Dyck, C H, Mulnard, R, Barakos, J, Gregg, K M, Liu, E, Lieberburg, I, Schenk, D, Black, R, Grundman, M

Volltext

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development f... von Leuzy, A., Ashton, N. J., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V., Hansson, O.

Volltext

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes von Magdalinou, N K, Paterson, R W, Schott, J M, Fox, N C, Mummery, C, Blennow, K, Bhatia, K, Morris, H R, Giunti, P, Warner, T T, de Silva, R, Lees, A J, Zetterberg, H

Volltext

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers von Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V., Hansson, O.

Volltext

CSF biomarkers for mild cognitive impairment von Blennow, K.

Volltext

Predicting MCI outcome with clinically available MRI and CSF biomarkers von HEISTER, D, BREWER, J. B, MAGDA, S, BLENNOW, K, MCEVOY, L. K

Volltext

Harmonized diagnostic criteria for Alzheimer's disease: recommendations von Morris, J. C., Blennow, K., Froelich, L., Nordberg, A., Soininen, H., Waldemar, G., Wahlund, L.‐O., Dubois, B.

Volltext

An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease von Lizama, B.N., North, H.A., Pandey, K., Williams, C., Duong, D., Cho, E., Di Caro, V., Ping, L., Blennow, K., Zetterberg, H., Lah, J., Levey, A.I., Grundman, M., Caggiano, A.O., Seyfried, N.T., Hamby, M.E.

Volltext

Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosis von Håkansson, I., Tisell, A., Cassel, P., Blennow, K., Zetterberg, H., Lundberg, P., Dahle, C., Vrethem, M., Ernerudh, J.

Volltext

CSF biomarkers predict a more malignant outcome in Alzheimer disease von WALLIN, A. K, BLENNOW, K, ZETTERBERG, H, LONDOS, E, MINTHON, L, HANSSON, O

Volltext

Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment von Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.‐O., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., Blennow, K., De Leon, M., DeCarli, C., Erkinjuntti, T., Giacobini, E., Graff, C., Hardy, J., Jack, C., Jorm, A., Ritchie, K., Van Duijn, C., Visser, P., Petersen, R.C.

Volltext

Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases von Minta, K., Brinkmalm, G., Janelidze, S., Sjodin, S., Portelius, E., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., Andreasson, U.

Volltext

Effective communications on invasive alien species: Identifying communication needs of Swedish domestic garden owners von Palmér, C., Wallin, A., Persson, J., Aronsson, M., Blennow, K.

Volltext

Identifying clinically useful biomarkers in neurodegenerative diseases–Moving from CSF to blood von Blennow, K.

Volltext

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease von Alawode, D. O. T., Heslegrave, A. J., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O´Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., Keshavan, A., Snellman, A., Gobom, J., Paterson, R. W., Schott, J. M., Blennow, K., Fox, N. C., Zetterberg, H.

Volltext

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment von Schedin‐Weiss, Sophia, Gaunitz, Stefan, Sui, Ping, Chen, Qiushi, Haslam, Stuart M., Blennow, Kaj, Winblad, Bengt, Dell, Anne, Tjernberg, Lars O.

Volltext

The role of beliefs, expectations and values in decision-making favoring climate change adaptation-implications for communications with European forest professionals von Blennow, K, Persson, J, Gonçalves, L M S, Borys, A, Dutc, I, Hynynen, J, Janeczko, E, Lyubenova, M, Mergani, J, Mergani ová, K, Peltoniemi, M, Petr, M, Reboredo, F, Vacchiano, G, Reyer, C P O

Volltext